Who are ε-Aminocaproic Acid (EACA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): low-dose epinephrine and tranexamic acid, Trasylol, Cyklokapron, Amicar, Tranexamic Acid (TXA), Tranexamic Acid / Sodium chloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aminocaproic-acid-eaca.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ε-Aminocaproic Acid (EACA) — Competitive Intelligence Brief

ε-Aminocaproic Acid (EACA) (ε-Aminocaproic Acid (EACA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic. Area: Other.

marketed Antifibrinolytic Plasminogen and plasmin Other Small molecule Live · refreshed every 30 min

Target snapshot

ε-Aminocaproic Acid (EACA) (ε-Aminocaproic Acid (EACA)) — Miller Orthopedic Specialists.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ε-Aminocaproic Acid (EACA) TARGET	ε-Aminocaproic Acid (EACA)	Miller Orthopedic Specialists	marketed	Antifibrinolytic	Plasminogen and plasmin
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid (TXA)	Tranexamic Acid (TXA)	NYU Langone Health	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid / Sodium chloride	Tranexamic Acid / Sodium chloride	University Hospital, Bordeaux	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic class)

Ain Shams University · 1 drug in this class
Bayer · 1 drug in this class
German Heart Center · 1 drug in this class
Institut Kassab d'Orthopédie · 1 drug in this class
Miller Orthopedic Specialists · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ε-Aminocaproic Acid (EACA) — Competitive Intelligence Brief. https://druglandscape.com/ci/aminocaproic-acid-eaca. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab